NASDAQ:AMGNAmgen Stock Price, Forecast & News

$258.24

+3.12 (+1.22 %)

(As of 07/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$252.87

Now: $258.24▼

$261.46

50-Day Range

$217.90

MA: $229.88▼

$258.24

52-Week Range

$173.12

Now: $258.24▼

$261.46

Volume3.34 million shs

Average Volume2.99 million shs

Market Capitalization$151.91 billion

P/E Ratio20.24

Dividend Yield2.48%

Beta0.94

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Amgen has received a consensus rating of Buy. The company's average rating score is 2.54, and is based on 16 buy ratings, 11 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $246.08, Amgen has a potential downside of 4.7% from its current price of $258.24.
Amount of Analyst Coverage
Amgen has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0 Community Rank

Outperform Votes
Amgen has received 1,397 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Amgen has received 926 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Amgen has received 60.14% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote “Outperform” if you believe AMGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Yield
Amgen pays a meaningful dividend of 2.48%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Amgen has been increasing its dividend for 9 years.
Dividend Coverage
The dividend payout ratio of Amgen is 43.18%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Amgen will have a dividend payout ratio of 38.12% next year. This indicates that Amgen will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $792,017.00 in company stock.
Percentage Held by Insiders
Only 0.36% of the stock of Amgen is held by insiders.
Percentage Held by Institutions
75.75% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Amgen are expected to grow by 7.90% in the coming year, from $15.56 to $16.79 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amgen is 20.24, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.46.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amgen is 20.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.10.
Price to Earnings Growth Ratio
Amgen has a PEG Ratio of 2.20. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Amgen has a P/B Ratio of 15.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.17 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:AMGN

Previous Symbol

CUSIP03116210

CIK318154

Webwww.amgen.com

Phone805-447-1000

Debt

Debt-to-Equity Ratio3.16

Current Ratio1.59

Quick Ratio1.28

Price-To-Earnings

Trailing P/E Ratio20.24

Forward P/E Ratio16.60

P/E Growth2.2

Sales & Book Value

Annual Sales$23.36 billion

Price / Sales6.50

Cash Flow$18.90 per share

Price / Cash Flow13.66

Book Value$16.28 per share

Price / Book15.86

Profitability

EPS (Most Recent Fiscal Year)$14.82

Net Income$7.84 billion

Net Margins32.03%

Return on Equity90.75%

Return on Assets15.44%

Miscellaneous

Employees23,400

Outstanding Shares588,250,000

Market Cap$151.91 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock been impacted by COVID-19 (Coronavirus)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AMGN shares have increased by 30.0% and is now trading at $258.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amgen?

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 11 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) announced its earnings results on Thursday, April, 30th. The medical research company reported $4.17 EPS for the quarter, beating the Zacks' consensus estimate of $3.70 by $0.47. The medical research company had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $6.01 billion. Amgen had a return on equity of 90.75% and a net margin of 32.03%. The business's quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.56 earnings per share. View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 4th. Shareholders of record on Monday, May 18th will be paid a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 annualized dividend and a dividend yield of 2.48%. The ex-dividend date of this dividend is Friday, May 15th. View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY20 earnings guidance on Thursday, April, 30th. The company provided earnings per share (EPS) guidance of $14.85-15.60 for the period, compared to the Thomson Reuters consensus estimate of $15.34. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.21 billion.

What price target have analysts set for AMGN?

28 analysts have issued 1 year price targets for Amgen's shares. Their forecasts range from $185.00 to $291.00. On average, they expect Amgen's stock price to reach $246.08 in the next year. This suggests that the stock has a possible downside of 4.7%. View analysts' price targets for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

1. According to Zacks Investment Research, "In 2020, while Amgen’s growth products like Prolia, Evenity, Repatha, Aimovig, Otezla and biosimilars will drive sales, increasing competition for its legacy products will continue to hurt the same. Amgen boasts a strong biosimilars portfolio. It is also progressing with its pipeline while regularly pursuing “external opportunities” such as the acquisition of Otezla and the recently acquired stake in China's BeiGene. Amgen also expects several important clinical data readouts from its innovative pipeline in 2020. However, pricing and competitive pressure are concerns. Amgen’s shares have outperformed the industry in the past one year. Estimates have gone down ahead of Q1 results due to uncertainty about the impact of the coronavirus pandemic on results. Amgen has a positive record of earnings surprise in recent quarters." (4/15/2020)
2. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
3. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)

Has Amgen been receiving favorable news coverage?

Headlines about AMGN stock have trended negative on Sunday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amgen earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days. View the latest news about Amgen.

Who are some of Amgen's key competitors?

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD) and AbbVie (ABBV).

Who are Amgen's key executives?

Amgen's management team includes the following people:

Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
Mr. David W. Meline, Exec. VP & CFO (Age 62)
Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by many different retail and institutional investors. Top institutional investors include Birch Capital Management LLC (0.00%), Gantzert Investment Co. LLC ADV (0.00%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%), Thomasville National Bank (0.00%), M&R Capital Management Inc. (0.00%) and Ellenbecker Investment Group (0.00%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View institutional ownership trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Nelson Van Denburg & Campbell Wealth Management Group LLC, M&R Capital Management Inc., and Gantzert Investment Co. LLC ADV. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar. View insider buying and selling activity for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Ellenbecker Investment Group, and Birch Capital Management LLC. View insider buying and selling activity for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $258.24.

How big of a company is Amgen?

Amgen has a market capitalization of $151.91 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings